News
STTK
4.850
-2.81%
-0.140
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Shattuck Labs (STTK) and Sarepta Therapeutics (SRPT)
TipRanks · 1d ago
Weekly Report: what happened at STTK last week (1102-1106)?
Weekly Report · 1d ago
Shattuck Labs’ RECEPTIVE Program Advances; Pantginis Maintains Buy Rating and $14 Price Target
TipRanks · 5d ago
Shattuck Labs reports Q3 EPS (14c), consensus (11c)
TipRanks · 5d ago
Shattuck Labs GAAP EPS of -$0.14 misses by $0.04
Seeking Alpha · 5d ago
*Shattuck Labs 3Q Research and Development Expenses $21.6M >STTK
Dow Jones · 5d ago
*Shattuck Labs 3Q Loss $25.2M >STTK
Dow Jones · 5d ago
Press Release: Shattuck Labs Reports Third -2-
Dow Jones · 5d ago
Press Release: Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Dow Jones · 5d ago
*Shattuck Labs 3Q Loss/Shr 14c >STTK
Dow Jones · 5d ago
Weekly Report: what happened at STTK last week (1026-1030)?
Weekly Report · 11/02 09:42
Weekly Report: what happened at STTK last week (1019-1023)?
Weekly Report · 10/26 09:42
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF), Icon (ICLR) and Shattuck Labs (STTK)
TipRanks · 10/20 13:40
Leerink Partners Keeps Their Buy Rating on Shattuck Labs (STTK)
TipRanks · 10/20 12:25
Weekly Report: what happened at STTK last week (1012-1016)?
Weekly Report · 10/19 09:42
Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology
Seeking Alpha · 10/12 18:31
Shattuck Labs Initiated at Buy by UBS
Dow Jones · 10/12 13:41
Weekly Report: what happened at STTK last week (1005-1009)?
Weekly Report · 10/12 09:45
Shattuck Labs initiated with a Buy at UBS
TipRanks · 10/11 23:40
UBS Initiates a Buy Rating on Shattuck Labs (STTK)
TipRanks · 10/11 22:56
More
Webull provides a variety of real-time STTK stock news. You can receive the latest news about Shattuck Labs, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About STTK
Shattuck Labs, Inc. is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is engaged in developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease and other inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. It is conducting a Phase I clinical trial in healthy volunteers. It is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.